Health Canada
Symbol of the Government of Canada

Common menu bar links

About Health Canada

Access to Information Requests Completed - November 2013

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

AER
Adverse Reaction Report (Adverse Event)
DIN
Drug Identification Number
DIN-HM
Homeopathic Medicine Number
MECS
Ministerial Executive Correspondence System
NPN
Natural Product Number
For the month of November 2013
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2010-00421 Documents pertaining to the Ontario Operational Centre of the Drug Compliance Verification and Investigation Unit's investigation into a complaint alleging advertising and labelling violations for Listerine Total Care for Sensitive Teeth Mouthwash. Disclosed in part 95
A-2011-00395 All briefing notes and memos regarding multiple sclerosis (MS) trials. (Jan 1, 2011 to Jun 29, 2011). Disclosed in part 25
A-2011-00697 Information regarding Cialis, DIN by Eli Lilly Canada Inc. Disclosed in part 198
A-2011-01252 All documents related to any communications regarding the 'housing crisis' in Attawapiskat. (Oct 1, 2011 to Dec 22, 2011). Disclosed in part 450
A-2011-01259 Information regarding Advil Nighttime. Disclosed in part 215
A-2011-01342 Information regarding K-Lyte Potassium Supplement - 20 Meq, NPN 80022848 by WellSpring Pharmaceutical Canada Corp. Disclosed in part 77
A-2011-01343 Information regarding K-Lyte Potassium Supplement - 10 Meq, NPN 80022845 by WellSpring Pharmaceutical Canada Corp. Disclosed in part 178
A-2011-01431 Information regarding Life Choice Ephedrine, NPN 80022453 by Life Choice Ltd. Disclosed in part 55
A-2011-01536 Information regarding Nicotine Lozenges / Thrive Lozenges, NPN 80007453, 80007461, 80007464. Disclosed in part 252
A-2011-01734 Information regarding Aura Cacia Eucalyptus Oil, NPN 80029508 by Aura Cacia (Frontier Essentials, LLC). Disclosed in part 77
A-2011-01749 All documents pertaining to shortages of medically necessary drugs. (Jan 1, 2011 to Mar 27, 2012). Disclosed in part 336
A-2012-00069 All records related to the Federal/Provincial/Territorial Task Group on Sodium. (Sep 1, 2011 to Oct 31, 2011). Disclosed in part 265
A-2012-00135 Information regarding PMS-Nabilone Pharmascience Inc. Disclosed in part 263
A-2012-01394 Information regarding Feramax 150, NPN 80013210 by Bio Syent Pharma Inc. Disclosed in part 593
A-2013-00055 Information regarding the following:
Ren Tox, DIN-HM 80012194
Vir-Tox, DIN-HM 80011686
Ly 111 Chronic, NPN 80007613
Disclosed in part 250
A-2013-00112 AERs for Cipralex. Report numbers: 000467451, 000469307, 000469692, 000470695, 000472923, 000474214, 000474947, 000475106, 000476850, 000477621, 000478563, 000485183, 000485896, 000487610, 000489399 and 000490689. Disclosed in part 27
A-2013-00202 AERs for Prozac. Report numbers: 00472498, 00473250 and 00477585. Disclosed in part 8
A-2013-00363 Information regarding the medical device OMNYX INTEGRATED DIGITAL PATHOLOGY SYSTEM - VL-4 SLIDE SCANNER, License number 90870 by OMNYX, LLC. Disclosed in part 20
A-2013-00388 List of all suppliers awarded communications contracts. (Jan 1, 2006 to Aug 8, 2013). Disclosed in part 49
A-2013-00417 Copy of all the briefing books prepared and being sent to the new Minister of Health Canada, Rona Ambrose. Disclosed in part 108
A-2013-00459 AERs for Humira. Report numbers: 000510683, 000508002, 000503121, 000501361 and 000500055. Disclosed in part 12
A-2013-00499 AERs for the following products/report numbers: Prozac (000489376), Cialis (000492123), Strattera (000500003, 000502055, 000503126, 000503904, 000508701, 000495218, 000501890, 000502846), Cymbalta (000500590, 000509789, 000509921, 000510192, 000510443, 000488017, 000492394, 000497710, 000501524, 000502583, 000504991, 000506176, 000508746, 000511619, 000491388, 000511527) Disclosed in part 58
A-2013-00541 AER for Oxaliplatin. Report number: 000499562. Disclosed in part 3
A-2013-00575 AERs for Aleve. Report numbers: 000496561, 000497214 and 000501925. Disclosed in part 10
A-2013-00594 AER for Docetaxel. Report number: 000497296. Disclosed in part 2
A-2013-00608 AER for Felodipine. Report number: 000493036. Disclosed in part 3
A-2013-00609 AER for Hydrochlorothiazide-Irbesartan. Report number: 000498561. Disclosed in part 8
A-2013-00643 AER for Eloxatin. Report number: 000507760. Disclosed in part 4
A-2013-00647 Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during August 2013. All disclosed 3
A-2013-00652 Documents that discuss, analyze, or consider the toxicity/human health implications of exposure to mercury, arsenic, poly-aromatic hydrocarbons, as well as other major forms chemical and organic compounds that are associated with the oil sands development in Alberta Canada. (Jan 1, 2009 to Sep 18, 2013). All disclosed 1,389
A-2013-00657 AER for Eloxatin. Report number: 000508288. Disclosed in part 3
A-2013-00659 AER for Eloxatin. Report number: 000509934. Disclosed in part 3
A-2013-00661 AER for Eloxatin. Report number: 000511365. Disclosed in part 2
A-2013-00662 AER for Eloxatin. Report number: 000508958. Disclosed in part 3
A-2013-00663 AER for Eloxatin. Report number: 000511229. Disclosed in part 2
A-2013-00665 AER for Eloxatin. Report number: 000511238. Disclosed in part 3
A-2013-00666 AER for Eloxatin. Report number: 000511218. Disclosed in part 3
A-2013-00667 AER for Eloxatin. Report number: 000507755. Disclosed in part 3
A-2013-00675 Copy of all organizational charts from the Natural Health Products Directorate (NHPD). (Jan 1, 2010 to Sep 13, 2013). Disclosed in part 139
A-2013-00676 All communications sent to employees from the Bureau of Product Review and Assessment in NHPD (Natural Health Products Directorate) for expression of interests, re acting and assignments opportunities etc. (Jan 1, 2010 to Sep 13, 2013). Disclosed in part 148
A-2013-00677 Information of the Director or Acting/Director (and BI-05 positions) related to the Bureau of Product Review and Assessment (BPRA) in NHPD (Natural Health Products Directorate) in regards to training, location of training, name of institution or organization providing the training, and all costs incurred by the department. (Jan 1, 2010 to Sep 13, 2013). Disclosed in part 78
A-2013-00700 List of briefing notes prepared for the minister. (Jul 15, 2013 to Sep 13, 2013). Disclosed in part 24
A-2013-00738 All communications between Minister Ambrose and department staff relating to heroin, special access program, drugs, Providence Health Care. (Sep 15, 2013 to Sept 24, 2013). No records exist 0
A-2013-00753 Data for the report: Drinking Water Advisories in First Nations Communities in Canada - A National Overview 1995-2007. Disclosed in part 77
A-2013-00754 Current list (as of October 1, 2013) of all drinking water advisories in First Nations communities, including the number of days the drinking water advisory has existed. All disclosed 5
A-2013-00766 MECS# 13-103704-195 Update: Nunavut Medical Travel Management Action Plan Sent to the Minister's Office 13-06-05 All disclosed 13
A-2013-00769 Copy of the three following documents contained in the Public Health Agency of Canada manual - functional classification system :
- description of operational functions;
- description of activities;
- description of administrative functions
All disclosed 158
A-2013-00774 AER. Report number: 000479093. Disclosed in part 1
A-2013-00781 During the 2012-2013 fiscal year, what amount has Health Canada spent annually for translation services:
- delivered by the Translation Bureau
- delivered by translation service providers from the private sector
All disclosed 1
A-2013-00785 Copy of the most recently compiled list of First Nations communities with drinking water advisories. All disclosed 5
A-2013-00794 All documents regarding the meeting of officials with representatives of Environmental Defence on August 2, 2011. Disclosed in part 33
A-2013-00809 All briefing notes regarding assisted suicide that were prepared for the minister in the lead-up to the Health Minister's meeting on October 4, 2013. Disclosed in part 13
A-2013-00822 Final drafts of all briefing materials sent to the Assistant Deputy Minister level for information management and information technology (IM/IT) and Security and above regarding IT security, IM security, data protection, and/or cyber security. (Jun 1, 2013 to Oct 16, 2013). All disclosed 62
A-2013-00835 Information with respect to studies conducted and study results regarding Estradiol and Prometrium. No records exist 0
A-2013-00840 All communications regarding Paul Webster (reporter) relating to Safety Code 6 and Environmental and Radiation Health Sciences Directorate (ERHSD). (Aug 1, 2012 to Oct 23, 2013). No records exist 0
A-2013-00844 All correspondence between Health Canada and Purdue Pharma related to the Managing Pain reference book or related materials. (Jan 1 2011 to Oct 22 2013). No records exist 0
A-2013-00845 All correspondence between Health Canada and John Moulder and Environmental and Radiation Health Sciences Directorate (ERHSD). (Jan 1, 2012 to Oct 23, 2013). No records exist 0
A-2013-00846 All correspondence between Health Canada and Frank Prato and Environmental and Radiation Health Sciences Directorate (ERHSD). (Jan 1, 2012 to Oct 23, 2013). No records exist 0
A-2013-00847 All correspondence between Health Canada and Kenneth Foster and Environmental and Radiation Health Sciences Directorate (ERHSD). (Jan 1, 2012 to Oct 23, 2013). No records exist 0
A-2013-00848 Per quarter sales of various Tobacco products. (Jan 1, 2005 to Sep 30, 2013). All disclosed 3
A-2013-00852 AER for Allerject (0.15 mg and 0.30 mg). Disclosed in part 2
A-2013-00862 Document pertaining to the money spent for the purchase of all the picture frames of the Prime Minister of Canada Stephen Harper in the offices of the Minister of Health. A copy of all of the policies of the Office of the Privy Council requesting that one or more pictures of the Prime Minister be installed in the offices of the Minister of Health. (Jan 1, 2006 to Oct 23, 2013). No records exist 0
A-2013-00868 Information regarding EYLEA (aflibercept). All exempted 0
A-2013-00873 AER. Report number: 000520882. Disclosed in part 1
A-2013-00874 AER. Report number: 000535819. Disclosed in part 1
A-2013-00875 AER. Report number: 000536451. Disclosed in part 3
A-2013-00876 AER. Report number: 000514691. Disclosed in part 1
A-2013-00877 AER. Report number: 000517753. Disclosed in part 1
A-2013-00878 AER. Report number: 000519575. Disclosed in part 1
A-2013-00879 AER. Report number: 000526584. Disclosed in part 1
A-2013-00880 AER. Report number: 000526948. Disclosed in part 1
A-2013-00881 AER. Report number: 000534010. Disclosed in part 1
A-2013-00882 AER. Report number: 000536168. Disclosed in part 4
A-2013-00885 AERs for Cymbalta. Report numbers: 000512001, 000515726, 000515752, 000515931, 000519120, 000521009, 000522466, 000523395, 000525780 and 000527057. Disclosed in part 11
A-2013-00901 AER for Plavix. Report number: 000515921. Disclosed in part 2
A-2013-00910 All communication between the Ontario Drug Program and other Provincial Drug Programs pertaining to the listing and pricing of single/dual source generics. (Oct 1, 2011 to Nov 1, 2013). No records exist 0
A-2013-00921 All communication between the Ontario Drug Program and other Provincial Drug Programs pertaining to the listing and pricing of single/dual source generics. (Nov 1, 2011 to Nov 4, 2013). No records exist 0
A-2013-00922 AER. Report number: 000493229. Disclosed in part 4
A-2013-00941 AERs for Xarelto. Report numbers: 000507642, 000510344, 000505936, 000503875, 000510204, 000505857, 000510724 and 000510249. Disclosed in part 9
A-2013-00945 AER for Diane-35. Report number: 000509674. Disclosed in part 1